

2023 年度 第 24 回 大学院セミナー

2023 年 6 月 7 日

| | |
|-------------------|--|
| 分野名 (責任者名)(内線) | 血液内科学分野 (原研内科) 責任者名 宮崎泰司 内線 7111 |
| 演題 | 第 177 回 原研研究集会 GENKEN research seminar |
| 講師等 | 原研内科 助教 田口正剛 先生 Masataka Taguchi, Assistant professor, Dept. of Hematology |
| 概要 | <p>Distinct Epigenetic Entities Reflecting Clinical and Molecular Features in Chronic Myelomonocytic Leukemia</p> <p>Chronic myelomonocytic leukemia (CMML) is a rare hematological malignancy characterized by dysplasia, abnormal proliferation of monocytic cells, and an elevated risk of transforming into acute leukemia. Genes involved in DNA methylation, such as <i>TET2</i> and <i>ASXL1</i>, are frequently affected, and hypomethylating agents (HMAs), Decitabine/Azacitidine, are widely used for the patients with CMML. However, only half of the patients have the benefit of HMAs and the survival of primary refractory cases is dismal. Therefore, better understanding of disease biology and molecular biomarkers predicting HMA response are strongly needed.</p> <p>Here, we analyzed 127 patients with CMML who were enrolled into the randomized phase III, DACOTA trial (NCT02214407, decitabine vs hydroxy urea), to determine new epigenetic entities reflecting their clinical and molecular features in CMML. We performed genome-wide mutation, gene expression and methylation analysis, then identified the disease subtypes associated with clinical features, overall survivals, and treatment response.</p> <p>In this lecture, I will present the results and discuss future directions.</p> |
| 開催日時 | 2023 年 6 月 28 日 (水) 17:30 ~ 18:30 |
| 開催方法 | Zoom |
| 備考 | <p>受講を希望する場合は、ID・パスワードをお教えしますので、必ずご連絡ください。(内線 7111 or Email: k-seven@nagasaki-u.ac.jp)</p> <p>If you would like to participate in this seminar and need Zoom ID and Password, please contact k-seven@nagasaki-u.ac.jp.</p> |

- 先端医療科学特論(基礎編)
- 先端新興感染症病態制御学特論
- 日本語(Japanese)
- 対面(Face to face)

- 先端医療科学特論(臨床編)
- 先端放射線医療科学特論
- 英語(English)
- オンライン(Online)